Pediatrix Medical Group, Inc.
MDHealthcareNASDAQMedical Care Facilities · Last scanned Sep 5, 2026
Scan Results
Daily timeframePediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company carries a $2.20B market cap, placing it firmly in the mid-cap category. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors.
Market Cap
$2.20B
Beta
0.65
P/E (TTM)
12.87
P/E (Fwd)
11.08
EPS (TTM)
$2.10
EPS (Fwd)
$2.44
ROE
20.4%
ROA
7.1%
Cash
$404.2M
Total Debt
$620.0M
Free CF
$160.8M
52W Change
58.6%
Annual Financials
Cash vs Debt
Where MD stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, MD finished 14.54% above its 150-day moving average ($23.11) and 15.49% above its 200-day moving average ($22.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MD overbought or oversold?
At the September 2, 2026 close, MD's RSI(14) was 49.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $404.2M in cash, though total debt stands at $620.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $160.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 20.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $1.97B (2022) to $1.91B (2025).
MD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pediatrix Medical Group, Inc.'s trajectory.